| Project/Area Number |
15K10604
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
Nakanishi Hiyoyuki 京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (40398376)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
浮村 理 京都府立医科大学, 医学(系)研究科(研究院), 教授 (70275220)
芦原 英司 京都薬科大学, 薬学部, 教授 (70275197)
中村 晃和 京都府立医科大学, 医学(系)研究科(研究院), 客員教授 (10381964)
上田 崇 京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (50601598)
三木 恒治 京都府立医科大学, 医学(系)研究科(研究院), 特任教授 (10243239)
|
|---|
| Research Collaborator |
SHIMIZU TERUKI 松下記念病院, 泌尿器科, 医長
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | γδT細胞 / 膀胱癌 / 膀胱注入療法 / 正所性膀胱癌モデル / γδＴ細胞 / MICA/B / 複合免疫療法 / 膀胱癌注入療法 |
|---|
| Outline of Final Research Achievements |
Human γδT cell immunotherapy has shown promising results in clinical trials; however, its antitumor efficacy is limited, including results in solid tumors. Ex-vivo expanded γδT cells show potent cytotoxicity against various types of cancer cells in a major histocompatibility complex (MHC)-unrestricted manner. Although several clinical trials of systemic cancer immunotherapy using γδT cells have been conducted, the results are unsatisfactory. The effector (γδT cell)-to-target (tumor cell) (E/T) ratio is an important factor determining cytotoxicity.A bladder instillation approach was used to increase the E/T ratio. The efficacy of γδT cell immunotherapy was examined in an orthotopic xenograft model. In Vivo Imaging System (IVIS) analysis revealed the potent cytotoxicity of weekly intravesical administration of γδT cells.The results indicate that the bladder infusion approach may be clinically applicable and could have beneficial effects in refractory bladder cancer.
|
